<DOC>
	<DOCNO>NCT01181310</DOCNO>
	<brief_summary>The drug , scopolamine , result short-term impairment cognitive function , attention , memory resemble see age Alzheimer 's disease . This study test capability individual combine dos MK-3134 current standard treatment : donepezil ( Aricept ) , reverse impairment , follow single dose scopolamine . Participants evaluate 5 different treatment period ( cross-over , double-dummy design ) : A : placebo match donepezil ( oral [ PO ] ) MK-3134 ( PO ) follow placebo scopolamine ( subcutaneous [ SQ ] ) ; B : placebo match donepezil ( PO ) MK-3134 ( PO ) , follow scopolamine SQ ; C : MK-3134 ( PO ) follow scopolamine SQ ; D : donepezil ( PO ) follow scopolamine SQ ; E : MK-3134 ( PO ) donepezil ( PO ) follow scopolamine SQ . The dos MK3134 , donepezil , scopolamine treatment arm specify drug administer . There 8 total visit treatment period , include 5 Treatment Visits require 14-day interval visit study-drug washout . Participants assess cognitive function treatment period Treatment Visits .</brief_summary>
	<brief_title>Placebo-Controlled Crossover Study Evaluate Donepezil MK-3134 Reversal Cognitive Impairment Associated With Scopolamine Administration ( 3134-005 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Participants eligible inclusion study : Male 18 40 year age . Nonsmokers , good health ( define protocol ) , willing follow studyrelated procedure . Participants eligible inclusion study : Had history illness , opinion study investigator specify protocol , might confound result study posed potential , additional risk participant participate study . Were take medication ( prescription , nonprescription , vitamin supplement herbal , illicit legitimate ) except acetaminophen . Had history significant head injury/trauma .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>dementia , cognitive impairment , neurodegeneration , Alzheimer 's , acetylcholine , AchE</keyword>
</DOC>